Related Experiment Videos
Oncogene expression is modulated by recombinant human interferon-beta in human breast-cancer cells
G Sica1, C Angelucci, L Marini
1Institute of Histology and Embryology, Catholic University of the Sacred Heart, Rome, Italy.
Abstract:
The effect of recombinant human interferon-beta on growth and oncoprotein expression was investigated in several human breast-cancer cell lines with different characteristics. All cell lines tested were sensitive to the antiproliferative action of the drug, regardless of their estrogen sensitivity. The maximal inhibition of cell proliferation was seen after 6 days of treatment. In estrogen-sensitive CG-5 and ZR-75-1 cells, but not in MDA-MB-453 estrogen-insensitive cells, a reduction in c-myc and c-erbB2 oncoproteins occurred after 48-72 hr and became more pronounced after 120-168 hr of treatment, suggesting that this down-regulation is not direct but is mediated by undefined molecular mechanisms. The time-course of the IFN-mediated decrease in oncoproteins seems to indicate that this event is not strictly related to the IFN-regulation of cell proliferation. The expression of c-erbB2 and c-myc was also analyzed, after recombinant human interferon-beta treatment, at the mRNA level in CG-5 cells. Surprisingly, no statistically significant variation of c-erbB2 or of c-myc mRNA was found either before or after 120-168 hr. Thus, we surmise that the observed reduction of oncoproteins may be due to post-transcriptional mechanisms.
Insights
Recombinant human interferon-beta inhibits breast cancer cell growth. It also reduces oncoprotein levels, suggesting post-transcriptional regulation mechanisms are involved.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Interferon-beta (IFN-β) is a cytokine with known antiproliferative effects.
- Oncoproteins like c-myc and c-erbB2 play crucial roles in cancer development.
- The precise mechanisms of IFN-β action on oncoprotein expression in breast cancer are not fully understood.
Purpose of the Study:
- To investigate the effect of recombinant human interferon-beta on the growth and oncoprotein expression in human breast cancer cell lines.
- To determine if the antiproliferative and oncoprotein-modulating effects of IFN-β are related to estrogen sensitivity.
- To elucidate the molecular mechanisms underlying IFN-β-induced oncoprotein reduction.
Main Methods:
- Treatment of various human breast cancer cell lines with recombinant human interferon-beta.
- Assessment of cell proliferation inhibition over a 6-day period.
- Analysis of c-myc and c-erbB2 oncoprotein levels at different time points (48-168 hours).
- Quantitative analysis of c-erbB2 and c-myc mRNA expression in response to treatment.
Main Results:
- All tested breast cancer cell lines showed sensitivity to the antiproliferative effects of interferon-beta.
- A significant reduction in c-myc and c-erbB2 oncoproteins was observed in estrogen-sensitive cell lines, but not in estrogen-insensitive ones.
- No significant changes in c-erbB2 or c-myc mRNA levels were detected, despite the decrease in protein levels.
- The observed oncoprotein down-regulation was not directly correlated with the antiproliferative effect and appeared to be mediated by post-transcriptional mechanisms.
Conclusions:
- Recombinant human interferon-beta exhibits antiproliferative activity against diverse human breast cancer cell lines.
- Interferon-beta treatment leads to a decrease in specific oncoproteins, suggesting a role for post-transcriptional regulation.
- The observed reduction in oncoproteins is likely mediated by mechanisms independent of direct transcriptional control or estrogen sensitivity.